A quick peek into the report
Table of Contents
1.1. Introduction
1.2. History of Injectable Drug Delivery Systems
1.3. Onset of Prefilled-Syringes
1.4. Introduction of Needle-Free Technology
1.5. Advantages of Prefilled Syringes Over Traditional Vial & Syringe System
1.6. Prefilled Syringes: Manufacturing and Packaging Challenges
1.7. Components of Prefilled Syringes
1.8. Benefits of Prefilled Syringes to the Pharmaceutical Companies
1.9. Rising Prevalence of Diabetes
1.10. Diabetes Prevalence in Different Countries (2017 Estimates)
1.11. Rising Prevalence of Diabetes and Use of Insulin Delivery Devices
2.1. Overview
2.2. Impact Analysis
2.3. Market Drivers
2.4. Market Restraints
2.5. Market Opportunities
3.1. Key Developments & Strategies
3.2. Recent Market Development Strategy Snapshot Analysis
3.3. Porter’s Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2 Bargaining Power of Buyers
3.3.3. Threat of New Entrant
3.3.4. Threat of Substitute
3.3.5. Intensity of Competitive Rivalry
3.4. Market Share Analysis
3.4.1. Market Share Analysis, Pen and Auto Injectors
3.4.2. Market Share Analysis, Prefilled
3.4.3. Market Share Analysis, Needle Free Injectors
3.5. Assumptions & Limitations for Analysis & Forecast of the Global Injectable Drug Delivery Market
4.1. Patent Landscape
4.2. Legal Requirements and Regulations
4.3. Consortiums, Associations and Regulatory Bodies
5.1. Introduction
5.2. Needle Free Injectors (Gas-based, Spring-Based and Others)
5.2.1. Global Needle Free Injector Market, By Region
5.3. Auto-Injectors (Reusable & Disposable)
5.3.1 Global Auto-Injectors Market, By Region
5.4. Pen Injectors (Reusable & Disposable)
5.4.1. Pen Injectors for Insulin
5.4.2. Global Pen Injectors Market, By Region
5.5. Prefilled Syringes
5.5.1. Global Prefilled Syringe Market, By Region
5.5.2. Glass Prefilled Syringes
5.5.3. Plastic Prefilled Syringes
5.5.4. Single Chamber Prefilled Syringes
5.5.4.1. Advantages of Hyaluronic Method of Single Chamber Prefilled Syringes Filling
5.5.5. Dual Chamber Prefilled Syringes
5.5.5.1 Some of the Marketed Dual Chambered Prefilled Syringes
5.5.6. Conventional Prefilled Syringe
5.5.7. Some of the lyophilized drugs which are used in prefilled syringe format
5.5.8. Safety Prefilled Syringes
5.5.8.1. Marketed Prefilled Safety Syringes
5.5.9. Customized Prefilled Syringes
5.6. Wearable Injectors (Qualitative)
6.1. Different Types of End User
6.1.1. Overview
6.1.2. Home Based
6.1.3. Hospital
6.1.4. Ambulatory Care
6.1.5. Clinics/Physician Offices
6.1.6 Others
6.2. Global Prefilled Syringes Market, by End Users
6.3. Global Needle Free Injector Market, by End Users
6.4. Global Auto-Injectors Market, by End Users
6.5. Global Pen Injection Market, by End Users
7.1. Overview
7.2. Different Route of Administration (Intravenous, Subcutaneous, intramuscular and Others)
7.3. Global Injectable Drug Delivery Market, By Route of Administration
8.1. Geographical Scenario
8.2. North America
8.2.1 The U.S.
8.2.2. Canada
8.3. Europe
8.3.1. The U.K.
8.3.2. Germany
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Netherlands
8.3.7. Switzerland
8.3.8. Belgium
8.3.9. Poland
8.3.10. Austria
8.3.11. Turkey
8.3.12. Rest of Europe
8.4. Asia Pacific (APAC)
8.4.1. Japan
8.4.2. China
8.4.3. Australia
8.4.4. South Korea
8.4.5. India
8.4.6. Malaysia
8.4.7. Indonesia
8.4.8. Rest of Asia Pacific
8.5. Latin America
8.5.1. Brazil
8.5.2. Mexico
8.5.3. Argentina
8.5.4. Rest of Latin America
8.6. Rest of the World (RoW)
8.6.1. K.S.A
8.6.2. Russia
8.6.3. South Africa
8.6.4. RoW
9.1. ALKERMES PUBLIC LIMITED COMPANY
9.1.1. Overview
9.1.2. Product Portfolio
9.1.3. Financials
9.1.3.1. Financial Summary
9.1.4. SWOT Analysis
9.2. Antares Pharma
9.2.1. Overview
9.2.2. Product Portfolio
9.2.3. Financials
9.2.3.1. Financial Summary
9.2.4. SWOT Analysis
9.3. Baxter International Inc.
9.3.1. Overview
9.3.2. Product Portfolio
9.3.3. Financials
9.3.3.1. Financial Summary
9.3.4. SWOT Analysis
9.4. Becton, Dickinson and Company
9.4.1. Overview
9.4.2. Product Portfolio
9.4.3. Financials
9.4.3.1. Financial Summary
9.4.4. SWOT Analysis
9.5. Elcam Medical
9.5.1. Overview
9.5.2. Product Portfolio
9.5.3. Corporate Summary
9.5.4. SWOT Analysis
9.6. Eli-Lilly and Company
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Financials
9.6.3.1. Financial Summary
9.6.4. SWOT Analysis
9.7. Gerresheimer AG
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Financials
9.7.3.1. Financial Summary
9.7.4. SWOT Analysis
9.8. Injex Pharma GmbH
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Corporate Summary
9.8.4. SWOT Analysis
9.9. Novartis AG
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Financials
9.9.3.1. Financial Summary
9.9.4. SWOT Analysis
9.10. NOVO NORDISK
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Financials
9.10.3.1. Financial Summary
9.10.4. SWOT Analysis
9.11. Pfizer, Inc.
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Financials
9.11.3.1. Financial Summary
9.11.4. SWOT Analysis
9.12. PharmaJet
9.12.1. Overview
9.12.2. Product Portfolio
9.12.3. Corporate Summary
9.12.4. SWOT Analysis
9.13. SANOFI
9.13.1. Overview
9.13.2. Product Portfolio
9.13.3. Financials
9.13.3.1. Financial Summary
9.13.4. SWOT Analysis
9.14. Schott AG
9.14.1. Overview
9.14.2. Product Portfolio
9.14.3. Financials
9.14.3.1. Financial Summary
9.14.4. SWOT Analysis
9.15. Terumo Corporation
9.15.1. Overview
9.15.2 Product Portfolio
9.15.3. Financials
9.15.3.1. Financial Summary
9.15.4. SWOT Analysis
9.16. Teva Pharmaceutical Industries Limited.
9.16.1. Overview
9.16.2 Product Portfolio
9.16.3. Financials
9.16.3.1. Financial Summary
9.16.4. SWOT Analysis
9.17. Vetter Pharma-Fertigung GmbH & Co. KG
9.17.1. Overview
9.17.2. Product Portfolio
9.17.3. Corporate Summary
9.17.4. SWOT Analysis
9.18. West Pharmaceutical Services, Inc.
9.18.1. Overview
9.18.2 Product Portfolio
9.18.3. Financials
9.18.3.1. Financial Summary
9.18.4. SWOT Analysis
9.19. Ypsomed Holding AG
9.19.1. Overview
9.19.2 Product Portfolio
9.19.3. Financials
9.19.3.1. Financial Summary
9.19.4. SWOT Analysis
10.1. Scope of the Report
10.2. Market Segmentation
10.3. Research Methodology
10.3.1. Primary Research
10.3.2 Secondary Research
10.3.3. Key Data Points From Primary Sources
10.3.4. Data Triangulation
10.3.5. Top-Down Approach (Segmental Analysis)
10.3.6. Bottom-Up Approach (Segmental Analysis)
10.4. Assumptions and Limitations
1 Key Players in the Market
2 Impact of Market Drivers
3 Impact of Market Restraints
4 Components of Prefilled Syringes
5 Number of Diabetics Worldwide and As Per region In 2017 and 2045 (20-79 years
6 Comparative Prevalence of Diabetes in Different Countries (20-79 years)
7 Impact Analysis of Market Dynamics
8 Region-wise Percentage of Total Population Aged 65 years & Above: 2015 & 2030
9 Factors Affecting the Bargaining Power of Buyer
10 Factors Affecting Threat of New Entrant
11 Factors Affecting the Threat of Substitute
12 Factors Affecting the Intensity of Competitive Rivalry
13 Patent Landscape
14 Consortiums, Associations and Regulatory Bodies
15 List of Some of the marketed products
16 Different types of Insulin Pen Injectors in Market
17 Regional Pen Injectors Market, By Value, 2016-2025 ($Million)
18 Regional Prefilled Syringe Market, By Value, 2016-2025 ($Million)
19 Regional Prefilled Syringe Market, By Volume, 2016-2025 (Million Units)
20 List of Some Dual Chamber Prefilled Syringes
21 List of Some Lyophilized Drugs which are used in Prefilled Syringe Format
22 List of Some Recently Marketed Prefilled Safety Syringes Technologies
23 Global Drug Delivery Market By Route of Admistration (2016-2025)
24 Percentages of Population Aged 60 Years and Above
25 ALKERMES PUBLIC LIMITED COMPANY: Overview
26 Antares Pharma: Overview
27 Baxter International Inc.: Overview
28 Becton Dickinson and Company: Overview
29 Elcam Medical: Overview
30 Eli-Lilly and Company: Overview
31 Gerresheimer AG: Overview
32 Injex Pharma GmbH: Overview
33 Novartis AG: Overview
34 NOVO NORDISK: Overview
35 Pfizer, Inc.: Overview
36 PharmaJet: Overview
37 SANOFI: Overview
38 Schott AG: Overview
39 Terumo Corporation: Overview
40 Teva Pharmaceuticals Industries Limited.: Overview
41 Vetter Pharma-Fertigung GmbH & Co. KG: Overview
42 West Pharmaceutical Services, Inc.: Overview
43 Ypsomed Holding AG: Overview
1 Chronic Conditions: Key Statistics: 2016
2 The Global Injectable Drug Delivery Market ($Million)
3 Types of Injector Devices
4 Global Injectable Drug Delivery Market, by Device, 2016
5 Global Injectable Drug Delivery Market, by Devices, 2025
6 Global Injectable Drug Delivery Market, by End Users, 2016
7 Global Injectable Drug Delivery Market, by End Users, 2025
8 Global Injectable Drug Delivery Market, by Route of Administration, 2016
9 Global Injectable Drug Delivery Market, by Route of Administration, 2025
10 Global Injectable Drug Delivery Market, by Region, 2016
11 Global Injectable Drug Delivery Market, by Region, 2025
12 Various Types of Injectable Drug Delivery Devices
13 Limitations of Hypodermic Needles
14 Key Milestones in History of Syringes
15 The Key Advantages of Needle-Free Technology
16 Advancements in Injectable Drug Delivery Technology
17 Advantages of Prefilled Syringes
18 Diabetes Statistics
19 Drivers Restraints and Opportunities
20 PER DAY COST SAVINGS VS. HOSPITAL
21 Share of the Key Strategies in the Global Injectable Drug Delivery Market
22 Porter’s Five Forces Analysis
23 Global Injectable Drug Delivery Market, 2016-2025 ($ Million)
24 Segmentation of Global Injectable Drug Delivery Market, By Device Type
25 Global Injectable Drug Delivery Market, By Device Type, 2016-2025 ($Million)
26 Global Needle Free Injector Market, 2016-2025 ($ Million)
27 Global Needle Free Injector Market, by type, 2016-2025 ($Million)
28 Advantages and Disadvantages of Needle Free Injectors
29 Types of Needle Free Injectors
30 Global Gas-Based Needle-Free Injectors Market, 2016-2025 ($Million)
31 Global Spring-Based Needle-Free Injectors Market, 2016-2025 ($Million)
32 Global Others Needle-Free Injectors Market, 2016-2025 ($Million)
33 Global Auto-Injector Market, 2016-2025 ($ Million)
34 Global Auto-injector Market, by Type, 2016-2025 ($Million)
35 Types of Pen Injectors
36 Global Pen Injector Market, 2016-2025 ($ Million)
37 Global Pen Injector Market, by type, 2016-2025 ($Million)
38 Global Prefilled Syringe Market, By Value, 2016-2025 ($Million)
39 Global Prefilled Syringe Market, By Volume, 2016-2025 (Million)
40 Global Glass Prefilled Syringes Market, By Value, 2016-2025 ($ Millions)
41 Global Glass Prefilled Syringe Market, By Volume, 2016-2025 (Million)
42 Global Plastic Prefilled Syringe Market, By Value, 2016-2025 ($Million)
43 Global Plastic Prefilled Syringe Market, By Volume, 2016-2025 (Million)
44 Global Single Chambered Prefilled Syringe Market, By Value, 2016-2025 ($Million)
45 Global Plastic Prefilled Syringe Market, By Volume, 2016-2025 (Million)
46 Global Dual Chambered Prefilled Syringe Market, By Value, 2016-2025 ($Million)
47 Global Dual Chambered Prefilled Syringe Market, By Volume, 2016-2025 (Million)
48 Global Customized Prefilled Syringes Market, by Value and Volume, 2016-2025 ($ Millions)
49 Global Customized Prefilled Syringe Market, By Volume, 2016-2025 (Million)
50 Types of End Users
51 Global Injectable Drug Delivery Market, by End Users (2016-2025)
52 Global Injectable Drug Delivery Market, by Home Based Treatment (2016-2025)
53 Global Injectable Drug Delivery Market, by Hospital (2016-2025)
54 Global Injectable Drug Delivery Market, by Ambulatory Care (2016-2025)
55 Global Injectable Drug Delivery Market, by Clinics/Physician Offices (2016-2025)
56 Global Injectable Drug Delivery Market, by Others (2016-2025)
57 Global Prefilled Syringes Market, by End Users (2016-2025)
58 Global Needle Free Market, by End Users 2016-2025)
59 Global Auto- Injectors Market, by End Users (2016-2025)
60 Global Pen Injection Market, by End Users (2016-2025)
61 Different Routes of Administration
62 Global Drug Delivery Market By Route of Admistration (2016-2025)
63 Global Injectable Drug Delivery Market, By Region
64 Global Injectable Drug Delivery Market, by region, 2016-2025 ($Million)
65 North America Injectable Drug Delivery Market, 2016-2025 ($Million)
66 North America Injectable Drug Delivery Market, by Country, 2016-2025 ($Million)
67 The U.S. Injectable Drug Delivery Market, 2016-2025 ($million)
68 The U.S. Injectable Drug Delivery Market, By Device, 2016-2025 ($million)
69 Canada Injectable Drug Delivery Market, 2016-2025 ($million)
70 Canada Injectable Drug Delivery Market, By Device 2016-2025 ($million)
71 Europe Injectable Drug Delivery Market, 2016-2025 ($Million)
72 The U.K. Injectable Drug Delivery Market, 2016-2025 ($million)
73 The U.K. Injectable Drug Delivery Market, By Device, 2016-2025 ($million)
74 Germany Injectable Drug Delivery Market, 2016-2025 ($million)
75 Germany Injectable Drug Delivery Market, By Device, 2016-2025 ($million)
76 France Injectable Drug Delivery Market, 2016-2025 ($million)
77 France Injectable Drug Delivery Market, By Device, 2016-2025 ($million)
78 Italy Injectable Drug Delivery Market, 2016-2025 ($million)
79 Italy Injectable Drug Delivery Market, By Device, 2016-2025 ($million)
80 Spain Injectable Drug Delivery Market, 2016-2025 ($million)
81 Spain Injectable Drug Delivery Market, By Device, 2016-2025 ($million)
82 Netherlands Injectable Drug Delivery Market, 2016-2025 ($million)
83 Netherlands Injectable Drug Delivery Market, By Device, 2016-2025 ($million)
84 Switzerland Injectable Drug Delivery Market, 2016-2025 ($million)
85 Switzerland Injectable Drug Delivery Market, By Device, 2016-2025 ($million)
86 Belgium Injectable Drug Delivery Market, 2016-2025 ($million)
87 Belgium Injectable Drug Delivery Market, By Device, 2016-2025 ($million)
88 Poland Injectable Drug Delivery Market, 2016-2025 ($million)
89 Poland Injectable Drug Delivery Market, By Device, 2016-2025 ($million)
90 Austria Injectable Drug Delivery Market, 2016-2025 ($million)
91 Austria Injectable Drug Delivery Market, By Device, 2016-2025 ($million)
92 Turkey Injectable Drug Delivery Market, 2016-2025 ($million)
93 Turkey Injectable Drug Delivery Market, By Device, 2016-2025 ($million)
94 Rest of Europe Injectable Drug Delivery Market, 2016-2025 ($million)
95 Rest of Europe Injectable Drug Delivery Market, By Device, 2016-2025 ($million)
96 Asia Pacific Injectable Drug Delivery Market, 2016-2025 ($Million)
97 Japan Injectable Drug Delivery Market, by value, 2016-2025 ($million)
98 Japan Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
99 China Injectable Drug Delivery Market, by value, 2016-2025 ($million)
100 China Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
101 Australia Injectable Drug Delivery Market, by value, 2016-2025 ($million)
102 Australia Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
103 South Korea Injectable Drug Delivery Market, by value, 2016-2025 ($million)
104 South Korea Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
105 India Injectable Drug Delivery Market, by value, 2016-2025 ($million)
106 India Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
107 Malaysia Injectable Drug Delivery Market, by value, 2016-2025 ($million)
108 Malaysia Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
109 Indonesia Injectable Drug Delivery Market, by value, 2016-2025 ($million)
110 Indonesia Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
111 Rest of Asia Pacific Injectable Drug Delivery Market, by value, 2016-2025 ($million)
112 Rest of Asia Pacific Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
113 Prevalence of Diabetes in Brazil & Mexico
114 Latin America Injectable Drug Delivery Market, 2016-2025 ($Million)
115 Brazil Injectable Drug Delivery Market, by value, 2016-2025 ($million)
116 Brazil Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
117 Mexico Injectable Drug Delivery Market, by value, 2016-2025 ($million)
118 Mexico Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
119 Argentina Injectable Drug Delivery Market, by value, 2016-2025 ($million)
120 Argentina Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
121 Rest of Latin America Injectable Drug Delivery Market, by value, 2016-2025 ($million)
122 Rest of Latin America Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
123 RoW Injectable Drug Delivery Market, 2016-2025 ($Million)
124 K.S.A Injectable Drug Delivery Market, by value, 2016-2025 ($million)
125 K.S.A Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
126 Russia Injectable Drug Delivery Market, by value, 2016-2025 ($million)
127 Russia Injectable Drug Delivery Market, by value, 2016-2025 ($million)
128 South Africa Injectable Drug Delivery Market, by value, 2016-2025 ($million)
129 South Africa Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
130 RoW Injectable Drug Delivery Market, by value, 2016-2025 ($million)
131 RoW Injectable Drug Delivery Market, by Devices 2016-2025 ($million)
132 ALKERMES PUBLIC LIMITED COMPANY: Product Portfolio
133 ALKERMES PUBLIC LIMITED COMPANY: Overall Financials (2015-2017)
134 ALKERMES PUBLIC LIMITED COMPANY: Revenue by Region (2015-2017)
135 ALKERMES PUBLIC LIMITED COMPANY: SWOT Analysis
136 Antares Pharma: Overall Product Portfolio
137 Antares Pharma: Overall Financials (2015-2017)
138 Antares Pharma: Product Sales by Geographic Location (2015-2017)
139 Antares Pharma: SWOT Analysis
140 Baxter International Inc.: Product Portfolio
141 Baxter International Inc.: Overall Financials (2015-2017)
142 Baxter International Inc.: Revenue by Global Business Units(2015-2017)
143 Baxter International Inc.: Revenue by Geographical Location (2015-2017)
144 Baxter International Inc.: SWOT Analysis
145 Becton Dickinson and Company : Overall Product Portfolio
146 Becton, Dickinson and Company : Overall Financials (2015-2017)
147 Becton, Dickinson and Company: Product Sales by Region (2015-2017)
148 Becton, Dickinson and Company: Revenue by Business Segment (2015-2017)
149 Becton, Dickinson and Company: Revenue by Sub-Segment (2015-2017)
150 Becton Dickinson and Company: SWOT Analysis
151 Elcam Medical: Product Portfolio
152 Elcam Medical: SWOT Analysis
153 Eli-Lilly and Company: Overall Product Portfolio
154 Eli-Lilly and Company: Overall Financials (2014-2017)
155 Eli-Lilly and Company : Revenue by Business Segment (2014-2017)
156 Eli-Lilly and Company: Revenue by Geography (2014-2017)
157 Eli-Lilly and Company: SWOT Analysis
158 Gerresheimer AG: Overall Product Portfolio
159 Gerresheimer AG: Overall Financials (2015-2017)
160 Gerresheimer AG: Revenue by Business Division (2015-2017)
161 Gerresheimer AG: Revenue by Geographical Location (2015-2017)
162 Gerresheimer AG: SWOT Analysis
163 Injex Pharma GmbH: Product Portfolio
164 Injex Pharma GmbH: SWOT Analysis
165 Novartis AG.: Overall Product Portfolio
166 Novartis AG : Overall Financials (2014-2017)
167 Novartis AG : Revenue by Region (2014-2017)
168 Novartis AG: Revenue by Business Segment (2014-2015)
169 Novartis AG: Revenue by Business Segment (2016-2017)
170 Novartis AG: SWOT Analysis
171 NOVO NORDISK: Overall Product Portfolio
172 NOVO NORDISK: Overall Financials (2015-2017)
173 NOVO NORDISK: Revenue by Business Segment (2015-2017)
174 NOVO NORDISK: Product Sales by Geographical Areas (2015-2017)
175 NOVO NORDISK: SWOT Analysis
176 Pfizer, Inc.: Product Portfolio
177 Pfizer Injectables: Product Portfolio
178 Pfizer Inc. : Overall Financials (2015-2017)
179 Pfizer Inc. : Revenue by Business Segment (2015-2017)
180 Pfizer, Inc. : Revenue by Geography (2015-2017)
181 Pfizer, Inc. : SWOT Analysis
182 PharmaJet: Product Portfolio
183 PharmaJet: SWOT Analysis
184 SANOFI: Overall Product Portfolio
185 SANOFI: Overall Financials (2015-2017)
186 SANOFI: Revenue by Business Segment (2015)
187 SANOFI: Revenue by Business Segment (2016-2017)
188 SANOFI: Revenue by Geography (2016-2017)
189 SANOFI: Revenue by Geography (2015)
190 SANOFI: SWOT Analysis
191 Schott AG: Overall Product Portfolio
192 Schott AG: Overall Financials (2015-2017)
193 Schott AG: Revenue by Geographical Location (2016-2017)
194 Schott AG: Revenue by Geographical Location(2015)
195 Schott AG: SWOT Analysis
196 Terumo Corporation: Overall Product Portfolio
197 Terumo Pharmaceutical Solutions: Product Portfolio
198 Terumo Corporation: Overall Financials (2015-2017)
199 Terumo Corporation: Revenue by Business Segment (2015-2017)
200 Terumo Corporation: Net Revenue by Region (2015-2017)
201 Terumo Corporation: SWOT Analysis
202 Teva Pharmaceuticals Industries Limited: Product Portfolio
203 Teva Pharmaceuticals Industries Limited.: Overall Financials (2015-2017)
204 Teva Pharmaceuticals Industries Limited.: Revenue by Business Segments (2015-2017)
205 Teva Pharmaceuticals Industries Limited.: Revenue by Geographical Location (2015-2017)
206 Teva Pharmaceuticals Industries Limited.: SWOT Analysis
207 Vetter Pharma-Fertigung GmbH & Co. KG: Product Portfolio
208 Vetter Pharma-Fertigung GmbH & Co. KG: SWOT Analysis
209 West Pharmaceutical Services, Inc.: Overall Product Portfolio
210 West Pharmaceutical Services, Inc.: Overall Financials (2015-2017)
211 West Pharmaceutical Services, Inc.: Revenue by Business Segment (2015-2017)
212 West Pharmaceutical Services, Inc.: Revenue by Geographical Location (2015-2017)
213 West Pharmaceutical Services, Inc.: SWOT Analysis
214 Ypsomed Holding AG: Product Portfolio
215 Ypsomed Holding AG: Overall Financials (2015-2017)
216 Ypsomed Holding AG: Revenue by Business Segments (2015-2017)
217 Ypsomed Holding AG: Revenue by Geographical Location (2015-2017)
218 Ypsomed Holding AG: SWOT Analysis
219 Global Injectable Drug Delivery Market Segmentation
Market Overview
The rising prevalence of chronic diseases as well as the growing geriatric population has lead to rapid changes in the healthcare scenario across the world. As per the WHO statistics, the global elderly population (aged 65 years and over) was 562 million in 2012 and it increased by 55 million in 2015. The increased prevalence of autoimmune and lifestyle diseases has led to unprecedented changes in the global healthcare needs. WHO further states that the global prevalence of diabetes, which is one of the chronic diseases, increased to 8.5% in adults over the age of 18 years in 2014, from 4.7% in 1980. This, consequently lead to an escalated demand for improved treatment and diagnostic services as diagnosis is the very first and crucial step of treating any ailment. The treatment of these chronic diseases involves the frequent administration of drugs, especially biologics and biosimilars. The increased interest of biopharmaceutical companies in the biologic medicine led to the demand for better drug packaging and delivery systems. Initially hypodermic needles and syringes were used. Nowadays, novel ways to administer drug have been developed like needle free injectors, autoinjectors, pen injectors & pre-filled syringes.
The purpose of the study is to gain a holistic view of the global injectable drug delivery market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centered upon conducting a detailed study of the solutions allied with the injectable drug delivery market. The market has been segmented into ‘devices’, ‘end-users’, ’route of administration’ and ‘geographical regions’.
The global injectable drug delivery market was estimated at $16.73 billion in 2016 and is estimated to grow over $37.47 billion by 2025. The rise in the geriatric population along with the increased prevalence of chronic diseases is expected to boost the demand for the injectable drug delivery devices and drive growth of the global market. The rise in the development and commercialization of biologics for various therapeutic indications is another reason for the increase in the demand for the injectable drug delivery systems. In order to overcome the limitations of needle-based injections, needle free technology for injections was developed.
The global injectable drug delivery device market can be segmented based on devices into needle free technology, auto-injectors & pen injectors. Based on route of administration, the market is segmented into intravenous, sub cutaneous, intraperitoneal, intramuscular and others.
Based on the end users, the market can be segmented into hospitals, clinics, homecare, ambulatory centers and others. The market for the homebased care is expected to reach $13,042.6 million by 2025. Geographically, the largest contributor to the growth of the global injectable drug delivery market in 2016 was Europe due to the presence of supportive governmental regulations and technologically advanced healthcare infrastructure apart from the increase in the prevalence of diseases. Europe was followed by North America in terms of revenue generation. The emerging markets of the RoW region are expected to register the highest CAGR in the forecast period due to rising healthcare expenditure and increasing patient awareness.
The injectable drug delivery devices provide safe and efficient method of drug delivery along with the advantage of self-administration. The market is expected to grow in the future due to technological development, high demand in the developing nations, rising prevalence of autoimmune and chronic diseases.
The report provides in-depth SWOT analysis of different key players of the market, supported by extensive financial summary of each. The key players for the market are Antares Pharma, Becton Dickinson and Company, Baxter International AG, Elcam Medical, Eli-Lilly, Sanofi, Gerresheimer AG, PharmaJet, Injex Pharma, Schott AG, and among others.
Key Questions Answered in this Report:
• What are the major market drivers, challenges, and opportunities in the global injectable drug delivery market?
• How did the needle less technology evolve, and what is its scope in the future?
• What were the market shares of the leading segments, and sub-segments of the global injectable drug delivery market in 2016 and what will be the value after 2025?
• How will each segment of the global injectable drug delivery market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2025?
• What are the influencing factors that may affect the market share of the key players?
• What are the key developmental strategies implemented by the key players to stand out in this market?
• What will be the growth rate of the pen injectors and autoinjector devices during the forecast period?
• Which product segment is expected to register the highest CAGR for the injectable drug delivery market?
• How will the homecare segment among the end users grow from 2018 to 2025?
• Which geographical location will contribute to the highest sales of the injectable drug delivery devices during the forecast period?
Report Description
The global healthcare scenario is changing rapidly owing to the rising geriatric population as well as the increasing prevalence of diseases. As per the WHO statistics, the global elderly population (aged 65 years and over) was 562 million in 2012 and it increased by 55 million in 2015. The rising prevalence of various chronic and autoimmune diseases had a profound effect on the global healthcare scenario. The WHO further states that the global prevalence of diabetes, which is one of the chronic diseases, increased to 8.5% in adults over the age of 18 years in 2014, from 4.7% in 1980. These factors have led to an escalated demand for improved treatment and diagnostic services as diagnosis is the very first and crucial step of treating any ailment. The treatment of these chronic diseases involves the frequent administration of drugs, especially biologics and biosimilars. Initially hypodermic needles and syringes were used. Nowadays novel ways to administer drug have been developed like needle free injectors, autoinjectors, pen injectors & prefilled syringes.
The injectable drug delivery devices market includes devices, such as auto-injectors, pen injectors and needle free injection technology. The market consists of various device products which can be used for various routes of administration, such as intravenous, subcutaneous/ intradermal, intra-peritoneal, intra-muscular and others.
These devices are being used for the administration of various medications especially for the biological products and proteins, such as insulin. The market analysis includes an in-depth examination of the key ecosystem players, and the key strategies and developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities, and challenges), and industry analysis.
The purpose of the study is to gain a holistic view of the global injectable drug delivery market in terms of various factors influencing it, such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centered upon conducting a detailed study of the solutions allied with the injectable drug delivery market. The market has been segmented into ‘devices’, ‘end-user’, ’route of administration’ and ‘geographical regions’. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the significant parameters that must be taken into consideration before entering the market.
This research report aims at answering questions related to various aspects of the global market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global injectable drug delivery market, and assesses the factors governing the same.
The key players for the market are Antares Pharma, Becton Dickinson and Company, Baxter International AG, Elcam Medical, Eli-Lilly, Sanofi, Gerresheimer AG, PharmaJet, Injex Pharma, and Schott AG, among others.
Global Injectable Drug Delivery Market
Focus on Devices, Competitive Landscape and Country - Analysis and Forecast (2018-2025)